Headlines FDA Approves Drug for Diabetic Eye Disease About 8 million people live with diabetic retinopathy. Published 4 years ago on May 15, 2019 By INVISION Staff Share Tweet TARRYTOWN, NY — Regeneron Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved Eylea Injection to treat all stages of diabetic retinopathy. “Millions of people have been robbed of their vision due to the progression of diabetic retinopathy,” said Dr. David Brown, an investigator for the PANORAMA trial and director of research at Retina Consultants of Houston. “The prevention of worsening diabetic retinopathy with EYLEA provides a compelling rationale for early treatment of patients with this disease, particularly since eyes dosed with EYLEA as infrequently as every 16 weeks showed significant improvements in the pivotal PANORAMA trial.” Approximately 8 million people live with diabetic retinopathy, a complication of diabetes characterized by damage to the blood vessels in the retina. The disease generally starts as non-proliferative diabetic retinopathy and often has no warning signs or symptoms. Over time, non-proliferative diabetic retinopathy often progresses to proliferative diabetic retinopathy, a stage in which abnormal blood vessels grow on the surface of the retina and into the vitreous cavity, potentially causing severe vision loss. “With today’s FDA approval, EYLEA has once again set a high bar for the treatment of diabetic eye diseases,” said Dr. George D. Yancopoulos, president and chief scientific officer at Regeneron. “The PANORAMA trial showed that by one year 20% of untreated patients developed proliferative diabetic eye disease, and EYLEA reduced this risk by 85% to 88% when administered using an every 16-week or eight-week dosing regimen, respectively. In fact, 80% of patients who received the EYLEA eight-week dosing regimen had significant improvement in their diabetic retinopathy.” Advertisement Eylea (aflibercept) is the only vascular endothelial growth factor (VEGF) inhibitor approved with two dosing options for diabetic retinopathy, allowing doctors to customize treatment to patients’ needs, according to a press release. In diabetic retinopathy, Eylea may be dosed every eight weeks following five initial monthly injections, or every four weeks. Related Topics:diabetic retinopathyLatest News Top click to Comment(Comment) Up Next Shopko Optical Acquisition Completed; 80 Stores to Become Freestanding Locations Don't Miss Longtime AOA Leader and Volunteer Dies at Age 62 SPONSORED VIDEO Crizal® Sapphire™ HR: Invisible Shield of Protection Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR, the latest and most advanced product in the Crizal No-Glare range, is now widely available across lab networks and through all major managed vision care providers. Crizal Sapphire HR is available with Essilor’s advanced lens designs such as Varilux® progressive lenses and Eyezen® enhanced single vision lenses. Click here to learn more. *External laboratory tests and internal technical tests – 2020. Compared to the competitor most known lens-brands by consumers (2019 external brand tracking in 11 countries). The word ’overall’ refers to anti-reflective coatings important criteria, ranked through an external quantitative consumer study – 2019. You may like Record Halloween Spending Expected: NRF 23 Painfully Relatable Memes About Working Holiday Retail Is Eyecare Ready for the Metaverse? Promoted Headlines On the Edger Maximizing Profit With In-House Finishing Visionix Made in Italy Italian Trade Agency Turn Patients Into Loyal Eyewear Shoppers Optify Advertisement Latest Trending Videos Headlines17 hours ago Record Halloween Spending Expected: NRF Photo Gallery19 hours ago 23 Painfully Relatable Memes About Working Holiday Retail Cover Stories20 hours ago Is Eyecare Ready for the Metaverse? Press Releases3 days ago Modern Optical Canada Announces New Collaboration with ZEISS Vision Care Canada Press Releases3 days ago IbisVision Launches Breakthrough Refraction Technology for Over-the-Internet Eye Prescriptions at Las Vegas Expo Photo Gallery4 weeks ago Celebrity Eyewear Pics Featuring SJP, Russell Crowe, ‘Half’ of Oasis, and Shakira (Of Course!) Photo Gallery19 hours ago 23 Painfully Relatable Memes About Working Holiday Retail Sponsored Content7 days ago Made in Italy Sponsored Content4 weeks ago Turn Patients Into Loyal Eyewear Shoppers America's Finest4 weeks ago Trading on a Good Name Sponsored Content4 weeks ago Turn Patients Into Loyal Eyewear Shoppers Sponsored Webinars2 months ago Shop! Masterclass Webinar: Sustainability for Retail: How Retailers Create Social, Environmental and Cultural Innovations Sponsored Content2 months ago Now Available: New Varilux® XR series™ Sponsored Webinars3 months ago Human-Centric Design in a Digital World: Creating Unexpected Moments That Inspire, Educate, and Connect at Retail Sponsored Content4 months ago The Very First of Its Kind: Introducing Ray-Ban Reverse Advertisement SubscribeBULLETINS Get the most important news and business ideas for eyecare professionals every weekday from INVISION. Advertisement Advertisement Most Popular Photo Gallery19 hours ago 23 Painfully Relatable Memes About Working Holiday Retail Sponsored Content7 days ago Made in Italy True Tales4 days ago The Farting Mom Chronicles: One Optician’s Terrible Tale Best of the Best1 week ago The One Tool a NY Practice Says Is ‘Essential’ in Targeting Ads to Website Visitors America's Finest6 days ago At This Alberta Practice, the Eyewear Is Global, the Exams Are Thorough and the Staff Are Valued Sponsored Content5 days ago On the Edger Maximizing Profit With In-House Finishing Headlines1 week ago National Pharmacy Chains Targeted for Unapproved Eyecare Products Columns7 days ago You’re In Optometry School… Now What?